^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE5 inhibitor

    Related drugs:
    5d
    Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer (clinicaltrials.gov)
    P3, N=188, Not yet recruiting, University Hospital, Rouen | Trial completion date: May 2028 --> Feb 2030 | Trial primary completion date: May 2028 --> Feb 2030
    Trial completion date • Trial primary completion date
    |
    sildenafil
    5d
    SHINE1: Sildenafil Plus Hypothermia to Treat Neonatal Encephalopathy (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Assistance Publique - Hôpitaux de Paris | Trial completion date: Jan 2028 --> May 2029 | Trial primary completion date: Feb 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    sildenafil
    5d
    MoD: Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension (clinicaltrials.gov)
    P3, N=28, Completed, Johns Hopkins University | Active, not recruiting --> Completed | N=100 --> 28 | Trial completion date: May 2026 --> Dec 2025 | Trial primary completion date: May 2026 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    sildenafil
    17d
    Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients (clinicaltrials.gov)
    P4, N=500, Recruiting, Mansoura University
    New P4 trial
    |
    sildenafil
    18d
    Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD (clinicaltrials.gov)
    P2, N=160, Recruiting, University of Alberta | Trial completion date: Dec 2025 --> May 2027 | Trial primary completion date: Dec 2025 --> May 2027
    Trial completion date • Trial primary completion date
    |
    sildenafil
    25d
    Enhanced antiproliferative and anti-inflammatory effects of combined metformin, tadalafil, and tamsulosin in a rat model of testosterone-induced benign prostatic hyperplasia. (PubMed, Life Sci)
    although individual treatments provided benefits, their combined use enhanced therapeutic outcomes through modulation of oxidative stress, inflammation, and androgenic activity in BPH management.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IGF2 (Insulin-like growth factor 2) • TGFB1 (Transforming Growth Factor Beta 1) • TGFB2 (Transforming Growth Factor Beta 2)
    |
    metformin
    1m
    FIBRONIE: Pilot Study on the Efficacy and Safety of FIBRORESTIL® as an Adjuvant Intralesional Treatment in Patients With Peyronie's Disease Receiving Standard Therapy (clinicaltrials.gov)
    P=N/A, N=38, Active, not recruiting, Lyx Institute
    New trial
    1m
    o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer (clinicaltrials.gov)
    P2, N=90, Completed, Tri-Service General Hospital
    New P2 trial
    |
    docetaxel
    1m
    ERASE PH-COPD: Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (clinicaltrials.gov)
    P3, N=200, Recruiting, Assistance Publique - Hôpitaux de Paris | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    2ms
    IMPROVE-FALD: IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease (clinicaltrials.gov)
    P1, N=15, Recruiting, Children's Mercy Hospital Kansas City | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    sildenafil
    2ms
    Sildenafil reduced neuroinflammation and improved white matter injury in a rat model of term neonatal hypoxic-ischemic encephalopathy. (PubMed, Sci Rep)
    Sildenafil significantly reduced neuroinflammation, improved white matter integrity, and supported oligodendrocyte recovery after neonatal HI. These findings highlight the potential of sildenafil as a neurorestorative therapy during the tertiary phase of injury in neonatal HIE.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • GFAP (Glial Fibrillary Acidic Protein) • OLIG2 (Oligodendrocyte Transcription Factor 2)
    |
    sildenafil
    2ms
    PK and Onset of Hezkue Oral Sildenafil Suspension After Alcohol Consumption (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Aspargo Labs, Inc
    New P1 trial